Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Atenor, Econocom, IRIS, TiGenix, Vopak: Benelux Equity Preview

May 20 (Bloomberg) -- The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.

The AEX-Index in Amsterdam advanced 0.5 percent to 350.84. Belgium’s Bel20 Index rose 0.6 percent to 2,717.02. Luxembourg’s LuxX Index fell 0.2 percent to 1,427.51.

Dutch stocks:

Royal Vopak NV (VPK NA): The world’s biggest chemical and oil storage company and Tianjin Bohai Chemical Industry Group said they plan to increase the storage capacity of the Tianjin Lingang liquefied-petroleum-gas terminal in China by 240,000 cubic meters. Vopak shares rose 0.2 percent to 31.61 euros.

Belgian stocks:

Atenor Group SA (ATEB BB): The Belgian developer said it will record a gain of 3.74 million euros ($5.35 million) on the sale of the final block of residential units of the Media Gardens project to Aedifica SA. Atenor shares increased 0.1 percent to 34.98 euros.

Econocom Group SA (ECONB BB): The computer-services company that bought Societe Generale SA’s ECS unit in October said the over-allotment option of its convertible-bond sale was fully exercised, boosting total proceeds to 84 million euros. Econocom shares gained 2.1 percent to 17.15 euros.

IRIS Group SA (IRIS BB): The Belgian software maker said first-quarter orders were a “little softer” than last year and second-half earnings will be “decisive” for the year. The shares advanced 0.1 percent to 37.13 euros.

TiGenix NV (TIG BB): The maker of the ChondroCelect cartilage-repair therapy said it consumed 3.4 million euros of cash in the first quarter and reported revenue of 400,000 euros for the period. The shares dropped 1.7 percent to 1.17 euros.

To contact the reporters on this story: John Martens in Brussels at jmartens1@bloomberg.net; Fred Pals in Amsterdam at fpals@bloomberg.net.

To contact the editors responsible for this story: Angela Cullen at acullen8@bloomberg.net; Andrew Rummer at arummer@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.